A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Completed · Phase 3

Conditions studied: Multiple Sclerosis

In brief

The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary objective of this study is to evaluate treatment effect over time in adult participants with RRMS treated with ALKS 8700.

Key facts

Study ID

NCT02634307

Run by

Biogen

People needed

1057

Starts

2015-12-10

Expected to finish

2021-11-11

Last updated by the study team

2022-07-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Subject is pregnant or breastfeeding or plans to become pregnant or begin breastfeeding at any point during the study and for 30 days after any study drug administration
• Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS
• History of clinically significant cardiovascular, pulmonary, gastrointestinal, dermatologic, psychiatric, neurologic (other than MS), and/or other major disease that would preclude participation in a clinical trial
• History of a myocardial infarction, including a silent myocardial infarction identified on ECG, or unstable angina
• NOTE: Other protocol defined Includison/Exclusion criteria may apply.

Where it is running

• Alkermes Investigational Site — Phoenix, Arizona, United States
• Alkermes Investigational Site — Phoenix, Arizona, United States
• Alkermes Investigational Site — Phoenix, Arizona, United States
• Alkermes Investigational Site — Tucson, Arizona, United States
• Alkermes Investigational Site — Berkeley, California, United States
• Alkermes Investigational Site — Loma Linda, California, United States
• Alkermes Investigational Site — Long Beach, California, United States
• Alkermes Investigational Site — San Diego, California, United States
• Alkermes Investigational Site — Basalt, Colorado, United States
• Alkermes Investigational Site — Centennial, Colorado, United States
• Alkermes Investigational Site — Denver, Colorado, United States
• Alkermes Investigational Site — Middlebury, Connecticut, United States
• Alkermes Investigational Site — Stamford, Connecticut, United States
• Alkermes Investigational Site — Washington D.C., District of Columbia, United States
• Alkermes Investigational Site — Atlantis, Florida, United States
• Alkermes Investigational Site — Bradenton, Florida, United States
• Alkermes Investigational Site — Jacksonville, Florida, United States
• Alkermes Investigational Site — Maitland, Florida, United States
• Alkermes Investigational Site — Naples, Florida, United States
• Alkermes Investigational Site — Ormond Beach, Florida, United States
• Alkermes Investigational Site — Sarasota, Florida, United States
• Alkermes Investigational Site — Tampa, Florida, United States
• Alkermes Investigational Site — Vero Beach, Florida, United States
• Alkermes Investigational Site — Atlanta, Georgia, United States
• Alkermes Investigational Site — Cullman, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.